With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
Two companies that faced criticism for high-priced drugs, Marathon and Mallinckrodt, have dropped out of the PhRMA trade association.
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
The drugs, approved by the FDA for children earlier this month, can run $100,000 for a course of treatment.
Such efforts have previously failed in the face of opposition from the drug industry, which questions their effectiveness and contends prices reflect research and development costs.
Amplifying the “patient voice,” those with the rarest afflictions are trained to become powerful advocates for new drugs and legislation that would help the industry.
Sen. Bernie Sanders’ bill to allow Americans to buy cheaper medicines from Canada would bypass a requirement that blocked past legislative efforts over two decades.
The Government Accountability Office said it will investigate potential abuses of the orphan drug program, which offers incentives to drugmakers to develop medicines for rare diseases.
Spending on consumer advertising by drugmakers has increased 62 percent since 2012.
Por primera vez, una investigación muestra que un nuevo, y costoso, medicamento llamado Repatha no sólo baja dramáticamente los niveles de colesterol malo (LDL) sino que también reduce el riesgo de ser hospitalizado y de morir.
A cholesterol-lowering drug called Repatha cuts the risk of heart attacks, strokes and heart-related death by 20 percent, according to a new study.
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
Two Democratic congressmen met with President Trump to seek his support for a bill to expand the government’s ability to negotiate drug prices, but it’s not clear it would have much impact or will gain support.
Amid an uproar over high drug prices, three GOP senators are asking the Government Accountability Office to investigate whether the Orphan Drug Act is being abused.
A new study shows that 83 percent of the largest patient advocacy groups take contributions from drug, medical device or biotech firms.
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.